Skip to main content

Krogulski Kenneth's Form 4 filing

Cumberland Pharmaceuticals Inc (CPIX) ยท filed Sep 30, 2022

Accession no.
0001209191-22-051665
Filed
Sep 30, 2022
Trade date
Aug 16-Sep 27, 2022
Filing delay
45 daysLate
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 30 non-derivative transactions. Open-market purchases total $8.00K. It was filed 45 days after the trade, past the 2-business-day deadline.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Krogulski KennethCIK 0001695580Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 16, 2022Common StockPPurchaseAcquired+110$2.35+$258.5194,010Direct
Aug 17, 2022Common StockPPurchaseAcquired+110$2.31+$254.1194,120Direct
Aug 18, 2022Common StockPPurchaseAcquired+110$2.23+$245.3194,230Direct
Aug 19, 2022Common StockPPurchaseAcquired+110$2.35+$258.5194,340Direct
Aug 22, 2022Common StockPPurchaseAcquired+110$2.51+$276.1194,450Direct
Aug 23, 2022Common StockPPurchaseAcquired+110$2.59+$284.9194,560Direct
Aug 24, 2022Common StockPPurchaseAcquired+110$2.59+$284.9194,670Direct
Aug 25, 2022Common StockPPurchaseAcquired+110$2.62+$288.2194,780Direct
Aug 26, 2022Common StockPPurchaseAcquired+110$2.55+$280.5194,890Direct
Aug 29, 2022Common StockPPurchaseAcquired+115$2.44+$280.6195,005Direct
Aug 30, 2022Common StockPPurchaseAcquired+115$2.38+$273.7195,120Direct
Aug 31, 2022Common StockPPurchaseAcquired+115$2.36+$271.4195,235Direct
Sep 1, 2022Common StockPPurchaseAcquired+115$2.39+$274.85195,350Direct
Sep 2, 2022Common StockPPurchaseAcquired+115$2.42+$278.3195,465Direct
Sep 6, 2022Common StockPPurchaseAcquired+115$2.15+$247.25195,580Direct
Sep 7, 2022Common StockPPurchaseAcquired+115$2.24+$257.6195,695Direct
Sep 8, 2022Common StockPPurchaseAcquired+115$2.22+$255.3195,810Direct
Sep 9, 2022Common StockPPurchaseAcquired+60$2.21+$132.6195,870Direct
Sep 12, 2022Common StockPPurchaseAcquired+115$2.46+$282.9195,985Direct
Sep 13, 2022Common StockPPurchaseAcquired+115$2.45+$281.75196,100Direct
Sep 14, 2022Common StockPPurchaseAcquired+115$2.51+$288.65196,215Direct
Sep 15, 2022Common StockPPurchaseAcquired+115$2.47+$284.05196,330Direct
Sep 16, 2022Common StockPPurchaseAcquired+115$2.49+$286.35196,445Direct
Sep 19, 2022Common StockPPurchaseAcquired+105$2.56+$268.8196,550Direct
Sep 20, 2022Common StockPPurchaseAcquired+105$2.54+$266.7196,655Direct
Sep 21, 2022Common StockPPurchaseAcquired+105$2.59+$271.95196,760Direct
Sep 22, 2022Common StockPPurchaseAcquired+105$2.51+$263.55196,865Direct
Sep 23, 2022Common StockPPurchaseAcquired+105$2.55+$267.75196,970Direct
Sep 26, 2022Common StockPPurchaseAcquired+105$2.49+$261.45197,075Direct
Sep 27, 2022Common StockPPurchaseAcquired+105$2.57+$269.85197,180Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Read the full filing on SEC EDGAR (opens in a new tab)